Navigation Links
Cancer stem cell subpopulation drives metastasis of human pancreatic cancer
Date:9/12/2007

Scientists have identified a distinct subpopulation of cancer stem cells (CSCs) that is responsible for metastasis of a deadly human pancreatic cancer. The research, published by Cell Press in the September issue of the journal Cell Stem Cell, provides insight into the role of CSCs in cancer initiation, progression, and metastasis and suggests new directions for development of more effective therapeutics.

Pancreatic adenocarcinoma ranks as the fourth leading cause of cancer death and is relatively incurable due to early metastatic spread and high resistance to radiation and chemotherapy. In order to better understand the pathology of this deadly cancer, scientists have recently begun to explore the role of CSCs in pancreatic tumors. CSCs are thought to be a small population of tumor cells that have similar properties to normal stem cells in that they are self-replicating and capable of giving rise to populations of differentiated cells. Dr. Christopher Heeschen from the Department of Surgery at Ludwig-Maximilians-University in Munich, Germany led a study to examine the role of CSCs in pancreatic cancer.

The researchers discovered that human pancreatic cancer tissue contains tumorigenic and chemotherapy resistant stem cells defined by expression of CD133, a surface marker expressed by a variety of normal and malignant stem cells. They identified a distinct subset of cells expressing both CD133 and the chemokine receptor CXCR4, which plays a key role in blood cell migration, in the invasive front of the tumor. Implantation of isolated CD133+/CXCR4+ cells into mice resulted in metastatic tumor development, identifying them as CSCs. Cancer metastasis was abolished by inhibiting CXCR4 or by transplanting CD133+/CXCR4- cells instead, underlining the importance of CXCR4 for the invasive cell behavior. Clinical studies revealed that tumor samples with a high number of CXCR4+ cells were more migratory and came from patients that suffered from more advanced metastatic disease. This important correlation may provide more accurate individual prognoses, allowing for improved selection of therapeutic agents.

These findings demonstrate for the first time that a specific CD133+/CXCR4+ cancer stem cell population present at the tumor-host interface is critically involved in pancreatic tumor metastasis. The further molecular characterization of the pancreatic CSCs identified in the present study will be crucial for the development of new therapeutic strategies to eliminate these tumorigenic and metastatic cells. This may eventually provide a more effective treatment for our patients suffering from this deadly disease. In this respect, the demonstrated possibility of expanding pancreatic CSCs in vitro will dramatically help us in the evaluation of drug efficacy, offers Dr. Heeschen.


'/>"/>

Contact: Nancy Wampler
nwampler@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Vitamin B12 can help in detecting cancers
6. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
7. Consensus on "Combination Therapy" for Breast Cancer
8. Cancers of Colon & Rectum linked to Cigarette Smoking
9. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
10. The Cancer Rumour mill working over time
11. Want skin cancer? Please have a cigarette
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: